abstract |
Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/ fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans. |